Related Experiment Video

Updated: Jun 23, 2026

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

Vanilloids in pancreatic cancer: potential for chemotherapy and pain management

M Hartel1, F F di Mola, F Selvaggi

  • 1Department of General Surgery, University of Heidelberg, Heidelberg, Germany.

Gut
|September 22, 2005
PubMed
Abstract

Insights

Vanilloids, like resiniferatoxin, induce apoptosis in pancreatic cancer cells and may treat cancer pain. Vanilloid 1 receptor (VR1) expression correlates with pain intensity in pancreatic cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Pain Management

Background:

  • Chemotherapy and pain management in pancreatic cancer are often suboptimal.
  • Vanilloids are emerging as potential therapeutic agents.
  • The vanilloid 1 receptor (VR1) is a target for pain treatment.

Purpose of the Study:

  • To investigate the effect of vanilloids on pancreatic cancer cell growth and apoptosis.
  • To determine if vanilloids can be used for pain treatment in pancreatic cancer via VR1.
  • To assess VR1 expression in pancreatic cancer and its correlation with pain.

Main Methods:

  • In vitro studies using resiniferatoxin on pancreatic cancer cells (apoptosis, cell growth).
  • Evaluation of VR1 expression at RNA and protein levels in human tissues.
  • Correlation of VR1 expression with pain intensity in a prospective patient cohort.

Main Results:

  • Resiniferatoxin induced apoptosis and decreased cell growth in pancreatic cancer cells.
  • VR1 was significantly upregulated in pancreatic cancer and chronic pancreatitis tissues.
  • VR1 expression correlated with pain intensity in pancreatic cancer patients.

Conclusions:

  • Vanilloids, such as resiniferatoxin, show potential for treating pancreatic cancer by inducing apoptosis.
  • Vanilloids may offer a novel treatment for neurogenic pain in pancreatic cancer patients.
  • Targeting VR1 could be a therapeutic strategy for pancreatic cancer and associated pain.

More Related Videos

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: